Integrated Filing — IndAS



General information about company
Scrip Code 544067
NSE Symbol INNOVACAP
MSEI Symbol NOTLISTED
ISIN INE0DUT01020
Name of company INNOVA CAPTAB LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 07-Aug-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 30-Jul-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment Drugs and Pharmaceutical products
Start date and time of board meeting 07-Aug-2025   15:30:00
End date and time of board meeting 07-Aug-2025   16:35:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party?
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.
Whether the company is a high value debt listed entity according to regulation 15 (1A)?
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?
Latest Date on which RPT policy is updated
Indicate Company website link for updated RPT policy of the Company
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? Yes



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 2869790000
Other income 43150000
Total income 2912940000
2 Expenses
(a) Cost of materials consumed 2034640000
(b) Purchases of stock-in-trade 12820000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -10820000
(d) Employee benefit expense 253450000
(e) Finance costs 27680000
(f) Depreciation, depletion and amortisation expense 90760000
(f) Other Expenses
1 Power and fuel 62760000 62760000
2 Stores and spares consumed 33950000 33950000
3 Repairs and maintenance 17430000 17430000
4 Packing charges 30680000 30680000
5 Lab consumables 9890000 9890000
6 Legal and professional fee 8000000 8000000
7 CSR expenditure 4860000 4860000
8 Rates, fees and taxes 8280000 8280000
9 Freight charges 10220000 10220000
10 Other expenses 45420000 45420000
Total other expenses 231490000
Total expenses 2640020000
3 Total profit before exceptional items and tax 272920000
4 Exceptional items 0
5 Total profit before tax 272920000
6 Tax expense
7 Current tax 51220000
8 Deferred tax 18750000
9 Total tax expenses 69970000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations 202950000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0
16 Total profit (loss) for period 202950000
17 Other comprehensive income net of taxes -2720000
18 Total Comprehensive Income for the period 200230000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 572250000
Face value of equity share capital 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 3.55
Diluted earnings (loss) per share from continuing operations 3.55
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 3.55
Diluted earnings (loss) per share from continuing and discontinued operations 3.55
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) The above standalone financial results of Innova Captab Limited have been prepared in accordance with and comply in all material aspects with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013 read with relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India Listing Obligations and Disclosure Requirements Regulations 2015 Listing Regulation as amended The results for the quarter ended 30 June 2025 are available on the Company website under investor information section and on the stock exchange website nThe above standalone financial results have been reviewed and recommended by Audit Committee at its meeting held on 07 August 2025 the Board of Directors at their meeting held on 07 August 2025 have approved the above results and taken them on record The statutory auditors of the Company have expressed an unmodified review conclusion on the standalone financial results for the quarter ended 30 June 2025 n nThe Company has only one reportable segment ie Drugs and pharmaceutical product as per Ind AS 108 Operating Segments specified under section 133 of the Companies Act 2013 Accordingly the disclosures as per the listing agreement are not applicable to the group n nThe figures of the last quarter ended 31 March 2025 as reported in these standalone financial results are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year Also the figures upto the end of the third quarter had only been reviewed and not subject to audit n



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments Textual Information(2)



Text Block
Textual Information(2) nThe Company has only one reportable segment ie Drugs and pharmaceutical products as per IndAS 108 Operating Segments specified under section 133 of the Companies Act 2013 Accordingly the disclosures as per the listing agreement are not applicable to the group n



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of defined benefit obligation -3640000 -3640000
Total Amount of items that will not be reclassified to profit and loss -3640000
2 Income tax relating to items that will not be reclassified to profit or loss -920000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0
5 Total Other comprehensive income -2720000





Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)
Mode of Fund Raising Public Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 27-Dec-2023
Amount Raised 3200000000
Report filed for Quarter ended 30-Jun-2025
Monitoring Agency Applicable
Monitoring Agency Name, if applicable CRISIL Ratings Limited
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation Not Applicable
Comments of the Audit Committee after review No Comments
Comments of the auditors, if any No Comments
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Repayment and/or prepayment, in part or in full, of certain outstanding loansof the company Not Applicable 1444000000 0 1444000000 0
2 Investment in the subsidiary, UML, for repayments and/or prepayment n part or full of outstandng loans availed by UML Not Applicable 236000000 0 236000000 0
3 funding working capital requirements of the company Not Applicable 720000000 0 720000000 0
4 general corporate purposes Not Applicable 531090000 0 542180000 0 The Board may take note that total expenditure initially estimated in connection with the Company Initial Public Offering amounted to Rs 479 million Subsequently the actual costs incurred were Rs 452 million thereby resulting in a net reduction in cost of Rs 27 million Out of this a sum of Rs 16 million is attributable to the selling shareholder for which the requisite payment has been duly remitted as of 30th June 2025 The residual balance of Rs 11 million pertaining to the Company has been appropriately allocated towards general corporate purposes Further as per the Object of the Offer approved if the actual utilization towards any of the stated objects is lower than the proposed deployment the balance shall be utilized for general corporate purposes This is subject to the condition that the total amount allocated towards general corporate purposes shall not exceed 25 percent of the gross proceeds from the Fresh Issue in accordance with applicable Regulation


Signatory Details
Name of signatory Neeharika Shukla
Designation of person Company Secretary and Compliance Officer
Place Panchkula
Date 07-Aug-2025




Format for Disclosing Outstanding Default on Loans and Debt Securities
Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date 0
B Of the total amount outstanding, amount of default as on date 0
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date 0
B Of the total amount outstanding, amount of default as on date 0
3. Total financial indebtedness of the listed entity including short-term and long-term debt 0